Actinic Keratosis

Categories: Cancer diseases, Genetic diseases, Skin diseases

Aliases & Classifications for Actinic Keratosis

MalaCards integrated aliases for Actinic Keratosis:

Name: Actinic Keratosis 12 74 36 54 15 17 71 32
Senile Hyperkeratosis 12
Seborrheic Keratosis 71
Sk - Solar Keratosis 12
Actinic Keratosis 12
Keratosis, Actinic 43
Solar Keratosis 12


External Ids:

Disease Ontology 12 DOID:8866
KEGG 36 H02429
ICD9CM 34 702.0
MeSH 43 D055623
NCIt 49 C3148
SNOMED-CT 67 201101007 856006
ICD10 32 L57.0
UMLS 71 C0022602 C0022603

Summaries for Actinic Keratosis

KEGG : 36 Actinic keratosis (AK) is a common cutaneous lesion associated with chronic exposure to ultraviolet (UV) radiation. AK presents scaly, erythematous papule or plaque and is considered the earliest clinically recognizable manifestation of squamous cell carcinoma.

MalaCards based summary : Actinic Keratosis, also known as senile hyperkeratosis, is related to keratosis and in situ carcinoma. An important gene associated with Actinic Keratosis is TP63 (Tumor Protein P63), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Endometrial cancer. The drugs Hydrogen peroxide and Mineral oil have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and kidney, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 74 Actinic keratosis (AK), sometimes called solar keratosis or senile keratosis, is a pre-cancerous area of... more...

Related Diseases for Actinic Keratosis

Diseases in the Actinic Keratosis family:

Keratosis, Familial Actinic

Diseases related to Actinic Keratosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 353)
# Related Disease Score Top Affiliating Genes
1 keratosis 33.1 TYR TP53 MMP9 MMP2 HRAS FLG
2 in situ carcinoma 31.5 TP53 MYC HRAS CDKN2A
3 keratosis, seborrheic 31.5 TP53 MC1R CDKN2A
4 lentigines 31.4 TYR MITF MC1R
5 squamous cell papilloma 31.3 TP53 HRAS CDKN2A
6 keratoacanthoma 31.1 TP53 MYC FLG
7 squamous cell carcinoma 31.1 TP63 TP53 TMC8 PTGS2 MYC MMP9
8 albinism 31.0 TYR MITF MC1R
9 lentigo maligna melanoma 31.0 MMP9 MMP2 MITF MC1R
10 skin carcinoma 30.8 VDR TYR TP53 TMC8 PTGS2 MC1R
11 skin squamous cell carcinoma 30.8 TP53 HRAS CDKN2A
12 bowenoid papulosis 30.7 PTGS2 FLG CDKN2A
13 skin disease 30.7 VDR TYR TP63 TP53 MITF MC1R
14 merkel cell carcinoma 30.6 TP53 MYC KRT20 CDKN2A
15 basal cell carcinoma 30.6 VDR TYR TP63 TP53 PTGS2 MMP9
16 rosacea 30.5 VDR MMP9 MMP3 IRF4
17 skin benign neoplasm 30.5 TP63 KRT20 HRAS
18 lymphangioma 30.5 TP53 PTGS2 MYC HRAS
19 vitiligo-associated multiple autoimmune disease susceptibility 1 30.5 TYR MITF MC1R
20 papilloma 30.4 TP63 TP53 PTGS2 PCNA KRT20 FLG
21 oculocutaneous albinism 30.4 TYR MITF MC1R
22 osteogenic sarcoma 30.1 VDR TP53 MYC MMP9 MMP2 CDKN2A
23 plasmacytoma 30.0 MYC IRF4 CDKN2A
24 melanoma 30.0 TYR TP53 MYC MMP2 MITF MC1R
25 myeloma, multiple 29.9 TP53 MYC MMP9 MMP2 IRF4 HRAS
26 cervical cancer 29.8 TP63 TP53 PTGS2 MYC MMP9 MMP2
27 renal cell carcinoma, nonpapillary 29.8 TYR TP53 MMP9 MMP2 MITF KRT20
28 esophageal cancer 29.7 TP63 TP53 PTGS2 MYC MMP9 MMP3
29 pancreatic cancer 29.2 TP53 PTGS2 MYC MMP9 MMP2 KRT20
30 gastric cancer 29.2 TP53 PTGS2 PCNA MYC MMP9 MMP3
31 actinic cheilitis 11.7
32 bowen's disease 10.7
33 extracranial arteriovenous malformation 10.6 MMP9 MMP2
34 vulvar intraepithelial neoplasia 10.6 TP53 CDKN2A
35 endometrial squamous cell carcinoma 10.6 TP53 CDKN2A
36 focal myositis 10.6 MMP9 MMP2
37 trachea carcinoma in situ 10.6 HRAS CDKN2A
38 ovarian seromucinous carcinoma 10.6 TP53 CDKN2A
39 esophagus verrucous carcinoma 10.6 TP53 CDKN2A
40 carcinosarcoma 10.6 TP53 HRAS CDKN2A
41 acute transverse myelitis 10.6 MMP9 MMP2
42 prostate squamous cell carcinoma 10.6 TP53 HRAS CDKN2A
43 spitz nevus 10.6 TP53 HRAS CDKN2A
44 tumor of exocrine pancreas 10.6 TP53 HRAS CDKN2A
45 adult malignant schwannoma 10.6 TP53 HRAS CDKN2A
46 chronic actinic dermatitis 10.6 MMP9 FLG
47 bone squamous cell carcinoma 10.6 TP53 MMP9 CDKN2A
48 nasal cavity cancer 10.6 TP53 HRAS CDKN2A
49 anus cancer 10.6 TP53 HRAS CDKN2A
50 atrophic vulva 10.6 KRT20 CDKN2A

Graphical network of the top 20 diseases related to Actinic Keratosis:

Diseases related to Actinic Keratosis

Symptoms & Phenotypes for Actinic Keratosis

MGI Mouse Phenotypes related to Actinic Keratosis:

45 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.48 CDKN2A CRLF3 HRAS IRF4 MC1R MITF
2 homeostasis/metabolism MP:0005376 10.42 CDKN2A CRLF3 HRAS IRF4 MITF MMP2
3 immune system MP:0005387 10.41 CDKN2A CRLF3 IRF4 MC1R MITF MMP2
4 behavior/neurological MP:0005386 10.4 CDKN2A HRAS MC1R MITF MMP9 MYC
5 cellular MP:0005384 10.38 CDKN2A IRF4 MC1R MITF MMP9 MYC
6 hematopoietic system MP:0005397 10.37 CDKN2A CRLF3 IRF4 MC1R MITF MMP2
7 cardiovascular system MP:0005385 10.35 CDKN2A HRAS MC1R MMP2 MMP9 MYC
8 endocrine/exocrine gland MP:0005379 10.32 CDKN2A HRAS MITF MYC PCNA PTGS2
9 mortality/aging MP:0010768 10.31 CDKN2A HRAS MITF MMP2 MMP9 MYC
10 integument MP:0010771 10.3 CDKN2A HRAS MC1R MITF MMP9 MYC
11 craniofacial MP:0005382 10.25 HRAS MC1R MITF MMP2 MYC TP53
12 digestive/alimentary MP:0005381 10.24 CDKN2A HRAS MMP9 MYC PTGS2 SOX10
13 neoplasm MP:0002006 10.23 CDKN2A HRAS IRF4 MC1R MMP2 MMP9
14 nervous system MP:0003631 10.21 CDKN2A HRAS MITF MMP2 MMP3 MMP9
15 limbs/digits/tail MP:0005371 10.16 MC1R MITF MMP9 MYC SOX10 TP53
16 no phenotypic analysis MP:0003012 10.14 CDKN2A HRAS MC1R MITF MYC PCNA
17 muscle MP:0005369 10.08 CDKN2A MMP2 MMP9 MYC PTGS2 TP53
18 hearing/vestibular/ear MP:0005377 10.04 MC1R MITF MYC TP53 TYR VDR
19 normal MP:0002873 10.02 HRAS MITF MMP2 MYC PTGS2 SOX10
20 pigmentation MP:0001186 9.87 CDKN2A MC1R MITF MYC SOX10 TP53
21 renal/urinary system MP:0005367 9.86 HRAS MITF MMP9 PTGS2 TP53 TP63
22 reproductive system MP:0005389 9.85 CDKN2A MITF MMP9 MYC PCNA PTGS2
23 respiratory system MP:0005388 9.56 CDKN2A HRAS MMP2 MMP9 PTGS2 SOX10
24 skeleton MP:0005390 9.4 CDKN2A HRAS MITF MMP2 MMP3 MMP9

Drugs & Therapeutics for Actinic Keratosis

Drugs for Actinic Keratosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 160)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Prilocaine Approved Phase 4 721-50-6 4906
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
Aminolevulinic acid Approved Phase 4 106-60-5 137
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
11 Retinol palmitate Phase 4
12 retinol Phase 4
13 Anti-Arrhythmia Agents Phase 4
14 Anti-Infective Agents, Local Phase 4
15 Anti-Bacterial Agents Phase 4
16 Lidocaine, Prilocaine Drug Combination Phase 4
17 Sodium Channel Blockers Phase 4
18 Diuretics, Potassium Sparing Phase 4
19 Anesthetics, Local Phase 4
20 Viscosupplements Phase 4
21 Pharmaceutical Solutions Phase 4
22 Adjuvants, Immunologic Phase 4
23 interferons Phase 4
24 Immunologic Factors Phase 4
25 Photosensitizing Agents Phase 4
26 Methyl 5-aminolevulinate Phase 4
27 Dermatologic Agents Phase 4
28 Emollients Phase 4
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
Selenious acid Approved, Investigational Phase 3 7783-00-8
Fluorouracil Approved Phase 3 51-21-8 3385
33 Protective Agents Phase 3
Ethylene Phase 3 74-85-1 6325
35 Trace Elements Phase 3
36 Micronutrients Phase 3
37 Nutrients Phase 3
38 Antioxidants Phase 3
39 Sodium Selenite Phase 3
40 Immunosuppressive Agents Phase 3
41 Antimetabolites Phase 3
42 Anesthetics Phase 3
43 Liver Extracts Phase 3
Afamelanotide Approved, Investigational Phase 2 75921-69-6
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
Alprostadil Approved, Investigational Phase 2 745-65-3 149351 5280723
Clindamycin Approved, Vet_approved Phase 2 18323-44-9 29029
Benzoyl peroxide Approved Phase 2 94-36-0 7187
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
Isotretinoin Approved Phase 2 4759-48-2 5282379 5538

Interventional clinical trials:

(show top 50) (show all 322)
# Name Status NCT ID Phase Drugs
1 A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis. Unknown status NCT01656226 Phase 4
2 A Double-blind, Randomized, Placebo-controlled, 2-way Crossover Study to Assess the Potential Effect of Topically Applied Imiquimod Cream on Atrial Ectopy in Patients With Actinic Keratosis Unknown status NCT01413763 Phase 4 Imiquimod cream 3.75%;Placebo cream
3 Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study Unknown status NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
4 Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
5 An Investigator-Initiated Study to Assess the Safety and Efficacy of Imiquimod 3.75% Cream When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands and Forearms Unknown status NCT01229319 Phase 4 Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm;Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm
6 Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face Unknown status NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
7 An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage Completed NCT03487588 Phase 4 A-101 Topical Solution
8 Vehicle-Controlled, Double-Blind Study to Assess the Safety and Efficacy of Imiquimod 5% Cream for the Treatment of Actinic Keratosis on the Upper Extremities Completed NCT00115154 Phase 4 Aldara (imiquimod) cream, 5%
9 Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage Completed NCT03697590 Phase 4 No curettage;Curettage
10 Comparison of the Efficacy and Tolerability of Solaraze for 3 vs. 6 Months in Patients With Mild to Moderate Actinic Keratosis Located at the Face and Head Completed NCT00204542 Phase 4 Diclofenac;Diclofenac
11 A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015% Completed NCT02446223 Phase 4 Inggenol Mebutate 0.015%
12 A Randomized Right/Left Clinical Trial to Evaluate the Use of Biafine Cream Versus Standard Care in Subjects With Actinic Keratosis Post Cryotherapy Completed NCT00695578 Phase 4 Biafine;Polysporin
13 Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
14 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp (LEIDA) Completed NCT00777127 Phase 4 Imiquimod;Diclofenac
15 Long-term Effects of Aldara® 5% Cream and Solaraze® 3% Gel in the Treatment of Actinic Keratoses on the Face or Scalp With Respect to the Risk of Progression to In-situ and Invasive Squamous Cell Carcinoma Completed NCT01453179 Phase 4 Imiquimod;Diclofenac
16 Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population Completed NCT00696488 Phase 4 Fluorouracil 0.5%
17 An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses Completed NCT00377273 Phase 4 fluorouracil cream 0.5%
18 Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents Completed NCT03279328 Phase 4 Topical Steroid Ointment;Skin Barrier Moisturier
19 A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT) Completed NCT02716714 Phase 4 ingenol mebutate gel 0.015%;ingenol mebutate gel 0.05%
20 Open-Label Safety and Pharmacokinetic Study of AldaraTM (Imiquimod) Cream, 5% for One, Two, or Three Treatment Cycles to Surface Areas Greater Than 25 cm2 With Actinic Keratosis Completed NCT00116649 Phase 4 imiquimod cream
21 A Comparison of the Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Density of Ablative Laser Channel in the Treatment of Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
22 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® PDT Completed NCT01000636 Phase 4
23 A Randomized, Parallel-Group, Vehicle-Controlled, Double-Blind Study of Topical Imiquimod 5% Cream Used as an Adjunct to Cryotherapy in the Management of Actinic Keratoses, With a Long-Term (1 Year) Follow-Up Completed NCT00110682 Phase 4 Imiquimod used as an adjunct to cryotherapy
24 Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients Completed NCT02866695 Phase 4 ingenol mebutate gel 0.015%
25 A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial Completed NCT01926496 Phase 4 Ingenol Mebutate Gel, 0.015%;Imiquimod Cream, 5%
26 Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp Completed NCT02406014 Phase 4 Ingenol Mebutate Gel, 0.015%;Diclofenac sodium gel 3%
27 UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
28 Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
29 An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands Completed NCT02251652 Phase 4 Ingenol Mebutate
30 A Randomized, Open-label, Assessor-blinded, Split-face Study of Imiquimod 5% Cream Applied After Cryotherapy of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
31 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
32 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
33 A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy Completed NCT02990221 Phase 4 Ingenol mebutate
34 A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
35 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
36 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention: A Long-term (3 Years) Follow-up of Prospective, Randomized, Multicenter-clinical Trial Recruiting NCT03642535 Phase 4 ALA
37 A Study to Investigate the Effect of Different Durations of Ameluz Application on Response to Treatment of Acral Actinic Keratoses Recruiting NCT03963102 Phase 4 Ameluz
38 An Exploratory, Open-label Study of Sequential Field-directed Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
39 Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
40 Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study Terminated NCT00944216 Phase 4 Salkera Emollient Foam
41 Phase III Comparative Study About the Use of 5% 5-fluorouracil Cream Versus Its Utilization as Agent for Sequential Superficial Peeling in the Treatment of Advanced Photoaging Unknown status NCT01405144 Phase 3 5-fluoruracil
43 A Randomized, Double-Blind, Vehicle-Controlled, PArallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face. Completed NCT02667275 Phase 3 A-101 Solution
44 An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face. Completed NCT02667288 Phase 3 A-101 Solution
45 To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis Completed NCT02385318 Phase 3 Ingenol Mebutate (Perrigo);Ingenol Mebutate (Reference);Placebo gel
46 Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest Completed NCT02361216 Phase 3 Ingenol Mebutate
47 To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis Completed NCT02459795 Phase 3 Ingenol Mebutate (Perrigo);Ingenol Mebutate (Reference);Placebo gel
48 A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face. Completed NCT02667236 Phase 3 A-101 Solution
49 A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Bioequivalence Study to Compare Sol-Gel Technologies' 5-FU Cream, With Efudex® (5-FU) Cream, and Both Active Treatments to a Vehicle Control, in the Treatment of Actinic Keratosis Completed NCT03727074 Phase 3 5-FU Cream;Efudex®;Vehicle
50 Phase 3 Study of Brand Generic and Placebo in Treatment of Actinic Keratosis Completed NCT01354717 Phase 3 Brand Carac;Generic 0.5% 5-fluorouracil cream

Search NIH Clinical Center for Actinic Keratosis

Cochrane evidence based reviews: keratosis, actinic

Genetic Tests for Actinic Keratosis

Anatomical Context for Actinic Keratosis

MalaCards organs/tissues related to Actinic Keratosis:

Skin, Testes, Kidney, Liver, Eye, Breast, Lymph Node

Publications for Actinic Keratosis

Articles related to Actinic Keratosis:

(show top 50) (show all 2467)
# Title Authors PMID Year
[Expression of cell proliferation and apoptosis biomarkers in skin spinocellular carcinoma and actinic keratosis]. 54 61
20098848 2009
The expression of p63 and p53 in keratoacanthoma and intraepidermal and invasive neoplasms of the skin. 54 61
19577853 2009
The characteristics of human papillomavirus expression and cell proliferation in actinic keratosis and Bowen's disease of the skin. 61 54
16905862 2006
Noncalcemic actions of vitamin D receptor ligands. 61 54
15798098 2005
Expression profiles of p63, p53, survivin, and hTERT in skin tumors. 61 54
15268709 2004
Expression of p53, bcl-2 and growth hormone receptor in atrophic type of actinic keratosis. 61 54
14757281 2004
Human papillomavirus infection in actinic keratosis and bowen's disease: comparative study with expression of cell-cycle regulatory proteins p21(Waf1/Cip1), p53, PCNA, Ki-67, and Bcl-2 in positive and negative lesions. 61 54
14562284 2003
Expression of p53, bcl-2 and growth hormone receptor in actinic keratosis, hypertrophic type. 61 54
12756585 2003
Large cell acanthoma. 54 61
12581141 2003
Expression of cell-cycle proteins p53, p21 (WAF-1), PCNA and Ki-67 in benign, premalignant and malignant skin lesions with implicated HPV involvement. 54 61
10429981 1999
Expression of proliferating cell nuclear antigen (PCNA) and apoptosis related antigen (LeY) in epithelial skin tumors. 54 61
9557786 1998
Evaluation of proliferating cell nuclear antigen as a surrogate end point biomarker in actinic keratosis and adjacent, normal-appearing, and non-sun-exposed human skin samples. 54 61
9162299 1996
Screening and Intervention for Skin Cancer in the Galapagos. 61
32355081 2020
Actinic keratosis arising in an epidermal cyst. 61
32461383 2020
Normal-subtracted preprocessing of Raman spectra aiming to discriminate skin actinic keratosis and neoplasias from benign lesions and normal skin tissues. 61
31853808 2020
Current therapies for actinic keratosis. 61
32012240 2020
High-risk body sites for actinic keratosis in outdoor and indoor workers: A retrospective review. 61
32561289 2020
Possible strategy to prevent recurrence of actinic keratosis after treatment field-direct. 61
32542965 2020
The validity of diagnostic and treatment codes for actinic keratosis in electronic health records. 61
31797355 2020
Cardiovascular Drug Use and Risk of Actinic Keratosis: A Case-Control Study. 61
32506248 2020
Detection of human papillomaviruses in paired healthy skin and actinic keratosis by next generation sequencing. 61
32222599 2020
High-frequency (20 MHz) high-intensity focused ultrasound: New Treatment of actinic keratosis, basal cell carcinoma, and Kaposi sarcoma. An open-label exploratory study. 61
32557832 2020
33% hydrogen peroxide as a Neoadjuvant treatment in the surgical excision of non-melanoma skin cancers: a case series. 61
32487195 2020
Principal component analysis of seven skin-ageing features identifies three main types of skin ageing. 61
31519034 2020
Pre-mRNA processing factor 3 enhances the progression of keratinocyte-derived cutaneous squamous cell carcinoma by regulating the JAK2/STAT3 pathway. 61
32483193 2020
An Investigation of the Stability of Patients' Treatment Preferences Over the Course of a Clinical Trial. 61
32540236 2020
Chronic expression of p16INK4a in the epidermis induces Wnt-mediated hyperplasia and promotes tumor initiation. 61
32483135 2020
Effects of MAL-PDT, ingenol mebutate and diclofenac plus hyaluronate gel monitored by high-frequency ultrasound and digital dermoscopy in actinic keratosis - a randomized trial. 61
31793041 2020
The use of ingenol mebutate to treat actinic keratosis in standard clinical practice: a prospective phase IV multicenter observational cohort study. 61
32301503 2020
Treatment monitoring of 5-Fluorouracil 0.5%/Salicylic Acid 10% lesion-directed therapy for actinic keratosis using dermoscopy and in-vivo reflectance confocal microscopy. 61
32478958 2020
Comparing the efficacy of field treatments for actinic keratosis: a critical appraisal of a randomized trial in the New England Journal of Medicine. 61
31529471 2020
Efficacy of lidocaine 7 %, tetracaine 7 % self-occlusive cream in reducing MAL-cPDT-associated pain in subjects with actinic keratosis: A randomized, single-blind, vehicle-controlled trial (The "3P-Trial"). 61
32294560 2020
Field cancerization treatment using topical photodynamic therapy: A comparison between two aminolevulinate derivatives. 61
31821900 2020
[Actinic keratoses : Current guideline and practical recommendations]. 61
32472149 2020
[Actinic keratosis]. 61
32468291 2020
Actinic keratosis: Treatment with imiquimod 3.75%-A comparative study between patients with previous in situ melanoma, patients with invasive melanoma and patients with negative history of melanoma. 61
32358885 2020
Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? 61
32367558 2020
Reflectance Confocal Microscopy of Pigmented Bowen's Disease: A Case Series of Difficult to Diagnose Lesions. 61
32518541 2020
Developing a risk prediction model for keratinocyte carcinoma in patients with actinic keratosis. 61
32390191 2020
Actinic Keratosis and Primary Care Physicians: Factors Affecting the Decision to Treat or Not. 61
32402371 2020
Treatment Motivations and Expectations in Patients with Actinic Keratosis: A German-Wide Multicenter, Cross-Sectional Trial. 61
32408601 2020
Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3,75% Cream. 61
32378272 2020
TERT promoter mutations in actinic keratosis before and after treatment. 61
31970758 2020
Reflectance confocal microscopy for noninvasive examination of nonmelanocytic tumors and virus-associated skin lesions in organ transplant recipients. 61
31802548 2020
Characterisation of the inflammatory response triggered by topical ingenol mebutate 0.05% gel in basal cell carcinoma. 61
31944277 2020
Hypertrophic lichenoid dermatitis immune-related adverse event during combined immune checkpoint and exportin inhibitor therapy: A diagnostic pitfall for superficially invasive squamous cell carcinoma. 61
32394425 2020
Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genes. 61
32461624 2020
Possible mechanisms of cancer prevention by nicotinamide. 61
32383227 2020
Association of Age-Related Cataract With Skin Cancer in an Australian Population. 61
32460312 2020
Assessment of 5-Aminolaevulinic Acid Photodynamic Therapy (ALA-PDT) in Chinese patients with actinic keratosis: Correlation of dermoscopic features with histopathology. 61
32424840 2020

Variations for Actinic Keratosis

Expression for Actinic Keratosis

Search GEO for disease gene expression data for Actinic Keratosis.

Pathways for Actinic Keratosis

Pathways related to Actinic Keratosis according to GeneCards Suite gene sharing:

(show all 39)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
7 12.33 TP53 PCNA MYC CDKN2A
8 12.31 TP53 MYC HRAS CDKN2A
9 12.23 TP53 MYC MMP9 MMP2 HRAS
10 12.19 TP63 TP53 PTGS2 MYC MMP9 HRAS
11 12.16 TP53 MYC MMP9 MMP3 MITF
12 12.12 TP53 MYC HRAS CDKN2A
13 12.05 TP53 PTGS2 MYC MMP9 MMP2
14 11.98 TP53 PTGS2 MYC MMP9
15 11.95 TP53 MYC HRAS CDKN2A
16 11.92 TP53 MYC HRAS CDKN2A
17 11.89 TP53 PCNA HRAS CDKN2A
18 11.89 VDR TP63 TP53 PCNA MMP2
19 11.8 TP53 PCNA MYC
20 11.8 PTGS2 MMP9 MMP3 MMP2
21 11.76 TP53 MYC MMP9
22 11.71 MYC MMP9 MMP2 MITF
23 11.68 TP53 MYC HRAS
24 11.67 TP53 MITF HRAS
25 11.65 TP53 MYC HRAS
26 11.64 MMP9 MMP2 HRAS
27 11.61 MMP9 MMP3 MMP2
Show member pathways
Show member pathways
11.56 PTGS2 MMP9 MMP3 MMP2
30 11.53 TP53 MMP2 CDKN2A
31 11.52 TP53 PTGS2 MYC
32 11.49 PTGS2 MYC HRAS
33 11.44 TP53 PCNA MYC
34 11.41 SOX10 MITF MC1R
35 11.33 TP53 PTGS2 MITF
37 11.22 TP53 PTGS2 MYC MMP9 MMP3 MMP2
38 11.08 TP53 MYC CDKN2A
Show member pathways
10.9 TP63 TP53 MYC CDKN2A

GO Terms for Actinic Keratosis

Cellular components related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 VDR TYR TP63 TP53 SOX10 PCNA
2 nuclear chromatin GO:0000790 9.17 VDR TP63 TP53 SOX10 MYC MITF

Biological processes related to Actinic Keratosis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 10.02 VDR TP63 TP53 SOX10 PCNA MYC
2 negative regulation of cell proliferation GO:0008285 9.97 VDR TP53 PTGS2 HRAS CDKN2A
3 negative regulation of apoptotic process GO:0043066 9.97 TP53 SOX10 PTGS2 MYC MMP9 MITF
4 cell cycle arrest GO:0007050 9.81 TP53 MYC HRAS CDKN2A
5 positive regulation of gene expression GO:0010628 9.8 VDR TP53 SOX10 MYC MITF HRAS
6 ephrin receptor signaling pathway GO:0048013 9.78 MMP9 MMP2 HRAS
7 Ras protein signal transduction GO:0007265 9.77 TP53 HRAS CDKN2A
8 cellular response to drug GO:0035690 9.76 TP53 SOX10 MYC
9 positive regulation of transcription, DNA-templated GO:0045893 9.76 TP63 TP53 SOX10 MYC MITF IRF4
10 extracellular matrix disassembly GO:0022617 9.74 MMP9 MMP3 MMP2
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 PTGS2 MYC MMP2
12 embryo implantation GO:0007566 9.72 PTGS2 MMP9 MMP2
13 collagen catabolic process GO:0030574 9.71 MMP9 MMP3 MMP2
14 pigmentation GO:0043473 9.7 TYR MITF MC1R
15 positive regulation of DNA binding GO:0043388 9.63 MYC MMP9 IRF4
16 cellular response to UV GO:0034644 9.62 TP53 PTGS2 PCNA MYC
17 cell aging GO:0007569 9.61 TP63 TP53 HRAS
18 ovulation GO:0030728 9.6 PTGS2 MYC
19 response to amyloid-beta GO:1904645 9.58 MMP9 MMP3 MMP2
20 regulation of neuroinflammatory response GO:0150077 9.54 PTGS2 MMP9 MMP3
21 cytokine-mediated signaling pathway GO:0019221 9.5 TP53 PTGS2 MYC MMP9 MMP3 MMP2
22 positive regulation of transcription by RNA polymerase II GO:0045944 9.36 VDR TP63 TP53 SOX10 MYC MITF

Molecular functions related to Actinic Keratosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.02 TYR TP63 TP53 SOX10 PCNA MMP9
2 DNA binding GO:0003677 9.96 VDR TP63 TP53 SOX10 PCNA MYC
3 DNA-binding transcription factor activity GO:0003700 9.91 VDR TP63 TP53 SOX10 MYC MITF
4 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.87 VDR TP63 TP53 SOX10 MYC MITF
5 chromatin binding GO:0003682 9.83 TP63 TP53 SOX10 PCNA MITF
6 transcription regulatory region DNA binding GO:0044212 9.76 TP63 TP53 SOX10 IRF4
7 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.63 TP63 TP53 SOX10 MYC MITF IRF4
8 protein binding GO:0005515 9.62 VDR TYR TP63 TP53 TMC8 SOX10
9 transcription factor binding GO:0008134 9.43 VDR TP53 SOX10 MYC IRF4 CDKN2A
10 MDM2/MDM4 family protein binding GO:0097371 9.4 TP63 TP53

Sources for Actinic Keratosis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....